Table 1.

Comparison of Transplant and Nontransplant Cohorts

Variable Treatment for CMLP
No. Transplant No. Hydroxyurea or Interferon
No. of patients   548   196   
Age, median (range) yr  548  35 (15-54) 196  41 (15-55)  <.001  
Male sex, No. (%)  548 331 (60)  196  119 (61)  .41  
WBC at Dx, median (range) N × 109/L  548  140 (3-850)  196 150 (15-489)  .004  
Hemoglobin at Dx, median (range), ×g/dL  479* 12 (2-17)  196  12 (4-16)  .06 
Platelets at Dx, median (range) N × 109/L 489* 419 (2-3,440)  196  412 (94-1,739)  .62 
% Blasts at Dx, median (range)  400* 1 (0-10) 196  2 (0-10)  <.0001  
Spleen size at Dx, median (range) cm  466* 3 (0-26)  196  5 (0-30)  .05 
Sokal score at Dx, No. (%)  337*  196   .48 
 Low risk   137 (41)   72 (37)  
 Intermediate risk   125 (37)   83 (42)  
 High risk  75 (22)   41 (21)  
Year of diagnosis <1988, No. (%)  548  294 (41)  196  94 (48)  .05 
Variable Treatment for CMLP
No. Transplant No. Hydroxyurea or Interferon
No. of patients   548   196   
Age, median (range) yr  548  35 (15-54) 196  41 (15-55)  <.001  
Male sex, No. (%)  548 331 (60)  196  119 (61)  .41  
WBC at Dx, median (range) N × 109/L  548  140 (3-850)  196 150 (15-489)  .004  
Hemoglobin at Dx, median (range), ×g/dL  479* 12 (2-17)  196  12 (4-16)  .06 
Platelets at Dx, median (range) N × 109/L 489* 419 (2-3,440)  196  412 (94-1,739)  .62 
% Blasts at Dx, median (range)  400* 1 (0-10) 196  2 (0-10)  <.0001  
Spleen size at Dx, median (range) cm  466* 3 (0-26)  196  5 (0-30)  .05 
Sokal score at Dx, No. (%)  337*  196   .48 
 Low risk   137 (41)   72 (37)  
 Intermediate risk   125 (37)   83 (42)  
 High risk  75 (22)   41 (21)  
Year of diagnosis <1988, No. (%)  548  294 (41)  196  94 (48)  .05 

*Not available for all patients.

Abbreviations: WBC, white blood cell count; Dx, diagnosis.

or Create an Account

Close Modal
Close Modal